On the stock market since 2021, it operates in the world of media and communication. It has 737 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
An average decline of 27% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
Executives buying with their own money is usually read as confidence in the company’s future.
An investor who bought at the very peak is down 99% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $251.7M a year. A small number, but proof the product has real buyers.
There is $39.0M in the vault; even if every debt were paid off, $36.2M would remain.
Over the last 12 months, company executives reported 26 buys and 21 sells. Management buying with its own money is usually read as a good sign.
A loss of $2.9M against $251.7M in annual sales. And on top of that, sales fell from the year before.
The stock trades 75% above the average analyst price target.
On our five-subject report card, BODY sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: BODY is a high-risk stock — not yet profitable, and its future rides on its product catching on.